Substituted bisphenylalkylurea compounds and methods of treating breast cancer
US12338204B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 9, 2019 |
| Grant date | Jun 24, 2025 |
| Priority date | — |
| Expiry date | Oct 28, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a composition and method for a therapeutic treatment that is able to combat triple negative breast cancers (TNBCs). The class of urea compounds acts by blocking at inhibiting the mTOR signaling pathway, which, as a central regulator of mammalian metabolism and physiology that when inhibited leads to the induction of autophagocytosis. The disclosed compounds are further capable of reinitiating the p53 cycle as well as inhibition of the BNIP3/BNIP3L pathway. The disclosed compounds also shows the ability to cross the blood-brain-barrier where metastases can form. This new drug has the potential to be a powerful new treatment to combat invasive TNBCs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.